What is B. Riley’s Estimate for TG Therapeutics Q3 Earnings?

TG Therapeutics, Inc. (NASDAQ:TGTX) – Research analysts at B. Riley raised their Q3 2025 EPS estimates for TG Therapeutics in a report issued on Monday, May 5th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earnings of $0.40 per share for the quarter, up from their previous estimate of $0.26. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. B. Riley also issued estimates for TG Therapeutics’ FY2026 earnings at $1.50 EPS, FY2027 earnings at $2.54 EPS and FY2028 earnings at $3.67 EPS.

TGTX has been the subject of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $40.80.

TG Therapeutics Stock Performance

NASDAQ:TGTX opened at $33.64 on Thursday. TG Therapeutics has a 1-year low of $15.16 and a 1-year high of $46.48. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The business has a 50 day moving average of $38.90 and a 200 day moving average of $33.56. The company has a market capitalization of $5.34 billion, a price-to-earnings ratio of -336.37 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.16). The firm had revenue of $120.86 million during the quarter, compared to analysts’ expectations of $117.07 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. TG Therapeutics’s revenue for the quarter was up 90.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.07) earnings per share.

Institutional Investors Weigh In On TG Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Deutsche Bank AG raised its holdings in shares of TG Therapeutics by 1.1% during the first quarter. Deutsche Bank AG now owns 148,705 shares of the biopharmaceutical company’s stock valued at $5,863,000 after acquiring an additional 1,685 shares in the last quarter. WealthShield Partners LLC purchased a new position in TG Therapeutics during the first quarter valued at $239,000. Thoroughbred Financial Services LLC bought a new stake in shares of TG Therapeutics during the 1st quarter valued at $324,000. PNC Financial Services Group Inc. grew its position in shares of TG Therapeutics by 27.0% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,019 shares of the biopharmaceutical company’s stock worth $356,000 after buying an additional 1,916 shares during the period. Finally, Commerce Bank increased its stake in shares of TG Therapeutics by 33.9% during the first quarter. Commerce Bank now owns 9,093 shares of the biopharmaceutical company’s stock valued at $359,000 after purchasing an additional 2,304 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.